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Trypanosomes are blood protozoan parasites that are capable of producing illness in the vertebrate host.
Within Australia, several native Trypanosoma species have been described infecting wildlife. However,
only Trypanosoma copemani has been associated with pathological lesions in wildlife hosts and more
recently has been associated with the drastic decline of the critically endangered woylie (Bettongia
penicillata). The impact that some trypanosomes have on the health of the vertebrate host has led to the
development of numerous drug compounds that could inhibit the growth or kill the parasite. This study
investigated and compared the in vitro susceptibility of two strains of T. copemani (G1 and G2) and one
strain of Trypanosoma cruzi (10R26) against drugs that are known to show trypanocidal activity (benz-
nidazole, posaconazole, miltefosine and melarsoprol) and against four lead compounds, two fenarimols
and two pyridine derivatives (EPL-BS1937, EPL-BS2391, EPL-BS0967, and EPL-BS1246), that have been
developed primarily against T.cruzi. The in vitro cytotoxicity of all drugs against L6 rat myoblast cells was
also assessed. Results showed that both strains of T. copemaniwere more susceptible to all drugs and lead
compounds than T. cruzi, with all IC50 values in the low and sub-mM range for both species. Melarsoprol
and miltefosine exhibited the highest drug activity against both T. copemani and T. cruzi, but they also
showed the highest toxicity in L6 cells. Interestingly, both fenarimol and pyridine derivative compounds
were more active against T. copemani and T. cruzi than the reference drugs benznidazole and pos-
aconazole. T. copemani strains exhibited differences in susceptibility to all drugs demonstrating once
again considerable differences in their biological behaviour.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The genus Trypanosoma comprises a large number of species
and subspecies that are capable of producing detrimental effects on
the host. T. cruzi for example, is a protozoan that causes Chagas
disease in humans and is an important contributor to heart disease
in Latin America (Kirchhoff, 1996). This parasite is able to infect
different marsupial species in America and has been shown to
produce inflammatory lesions in tissues similar to those seen in
human infections (Barr et al., 1991; Carreira et al., 1996). Further-
more, trypanosomes from the “T. brucei complex” are pathogenic
trypanosomes from Africa that cause sleeping sickness in humans,A. Botero).
University, 90 South Street,
Ltd on behalf of Australian Society fand nagana in vertebrate animals. Common signs of the infection in
humans are swollen lymph nodes, fever, anaemia, oedema, and
neurological involvement. Other trypanosomes that are considered
non-pathogenic may cause harm when they find a new or naïve
vertebrate host. For example, within Australia, the accidental
introduction of the exotic T. lewisi to Christmas Island is hypothe-
sized to have caused a collapse in the population of the endemic rat
Rattus macleari to the point of complete extinction (Pickering and
Norris, 1996; Wyatt et al., 2008). More recently, a genotype of a
native Australian trypanosome, Trypanosoma copemani G2, was
associated with the rapid and substantial population decline of the
critically endangered woylie (Bettongia penicillata), which saw 90%
of the population crash over 10 years (Botero et al., 2013; Wayne
et al., 2013a, 2013b). Although, two genotypes of T. copemani have
been isolated from the blood of woylies (T. copemani G1 and G2),
only T. copemani G2 has been found infecting several tissues in the
woylie and other endangered marsupials such as the southernor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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froii). Intracellular structures suggestive of amastigotes as well as
extensive inflammatory cell infiltrates and tissue damage have
been found in woylie tissues infected with T. copemani G2, thus
demonstrating pathogenic potential previously not associated with
trypanosomes fromwildlife in Australia (Botero et al., 2013). In vitro
experiments have also confirmed T. copemani capability to infect
cells (Botero et al., 2016). Both genotypes of T. copemani firmly
clustered in amonophyletic assemblagewith different genotypes of
T. copemani previously described in the blood of other critically
endangered and vulnerable Australian marsupials including Gil-
bert's potoroos (Potorous gilbertii), quokkas (Setonix brachyurus)
(Austen et al., 2009), and koalas (Phascolarctos cinereus) (McInnes
et al., 2011). 18SrDNA and gGAPDH T. copemani phylogenies that
included pathogenic trypanosomes such as T. cruzi and T. brucei
have shown a closer relationship between T. copemani and T. cruzi
compared with T. brucei and allied species (Austen et al., 2009;
McInnes et al., 2011).
The impact that pathogenic trypanosomes have on the health of
the vertebrate host has led to the development of numerous drug
compounds that could inhibit or kill the parasite. Benznidazole (N-
benzyl-2-nitro-1-imidazole-acetamide) for example, is currently
used for the treatment of T. cruzi infections. Despite this drug not
being completely effective, especially in the chronic stage of the
disease (Soeiro and de Castro, 2009; Organization, 2010; Jackson
et al., 2010; Batista et al., 2011; Alonso-Padilla and Rodriguez,
2014), it is the main drug therapy available to treat the disease.
Posaconazole, an ergosterol biosynthesis inhibitor, has also shown
potent in vitro and in vivo activity against T. cruzi (de Figueiredo
Diniz et al., 2013). Drugs currently used to treat other trypanoso-
matid infections such as African trypanosomiasis and leishma-
niansis include melarsoprol, eflornithine, miltefosine, and also
nifurtimox. (Melarsoprol (2-(4-(4,6-diamino-1,3,5-triazin-2-
ylamino)phenyl)-1,3,2-dithiarsolan-4-yl)methanol) is an arsenical
drug that has been used against late-stage infections with T. brucei
subspecies (Denise and Barrett, 2001), and miltefosine (hex-
adecylphosphocholine) is an alkylphosphocholine that was the first
and still the only oral drug that can be used to treat visceral and
cutaneous leishmaniasis (Dorlo et al., 2012a, 2012b). Eflornithine
(a-difluoromethylornithine) an ornithine decarboxylase inhibitor,
has been shown to be active against second stage T.b. gambiense
(Steverding, 2010), and has been used in conjunction with nifurti-
mox (E-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-
nitrofuran-2-yl)methanimine) against T. brucei (Alirol et al., 2013).
Although, all these drugs are the main treatment used to combat
these trypanosomatid infections, they are less than ideal due to
toxicity, adverse side effects and in some cases lack of efficacy
against intracellular parasites (Milord et al., 1992; Castro et al.,
2006; Pinazo et al., 2013; Hasslocher-Moreno et al., 2012). At-
tempts to develop new compounds with potent activity against
trypanosomes and low toxicity in mammalian cells has led to the
discovery of different ergosterol biosynthesis inhibitor compounds
with demonstrated in vitro and in vivo activity against all T. brucei
subspecies and T. cruzi. For example, inhibition of T. cruzi CYP51
(sterol 14a-demethylase) has been shown to affect sterol compo-
sition and consequently cause damage to the parasites ultrastruc-
ture leading to their death (Lepesheva and Waterman, 2011;
Hargrove et al., 2013; Keenan et al., 2013c). Recently developed
and optimized lead compounds include the ergosterol biosynthesis
inhibitors EPL-BS1937, EPL-BS2391, EPL-BS0967, and EPL-BS1246.
All have recently been shown to be non-azole inhibitors of
T. cruzi CYP51 (Hargrove et al., 2013; Keenan et al., 2013a; Keenan
et al., 2013b).
Considering not only the potential pathogenicity of T. copemani
G2 in thewoylie, but also that this parasite has been found infectingother critically endangered and vulnerable Australian marsupials,
there is the need to evaluate the in vitro susceptibility of T. copemani
to drugs as first steps towards the understanding of possible ways
to ameliorate its impact on threatened populations. Therefore, the
aims of this paper are to investigate and compare the in vitro sus-
ceptibility of T. copemani G1 and G2, and T. cruzi to reference drugs
and compounds currently used against pathogenic
trypanosomatids.
2. Materials and methods
2.1. Parasites and cells
T. copemani strains G1 and G2 isolated from the blood of woylies
(Botero et al., 2013), and the T. cruzi strain 10R26 were grown and
maintained as epimastigotes by successive passages every 3 days at
28 C in RPMImedium containing 10% foetal calf serum (FCS), 5 mg/
ml penicillin-streptomycin and 2.5 mg/L haemin. L6 cells (skeletal
myoblast cells) purchased from the American Type Culture
Collection were used in the drug toxicity assays. Cells were grown
in RPMI medium supplemented with 10% FCS at 37 C and 5% CO2.
2.2. Test compounds
Miltefosine and melarsoprol were kindly provided by Dr
Vanessa Yardley (London School of Hygiene and Tropical Medicine,
UK). Benznidazole tablets (Rochagan - 100 mg) were purchased
from Roche (Rio de Janeiro, Brazil). Posaconazole was purchased as
an oral suspension (Noxafil Schering Corporation, 40 mg/mL) and
isolated from the suspension by dilution with water and centrifu-
gation, followed by extraction and recrystallization from hot i-
propyl alcohol (Keenan et al., 2012). Four CYP51 inhibitor lead
compounds that have been shown to be inhibitors of T. cruzi,
incluiding two pyridine derivatives EPL-BS0967 and EPL-BS1246
(PDB1 and PDB2 respectively - also known as UDD and UDO), and
two non-azole antifungal fenarimoles EPL-BS1937 and EPL-BS2391
(FN1 and FN2 respectively) were kindly provided by Epichem Pty
Ltd (Hargrove et al., 2013; Keenan et al., 2012; Keenan et al., 2013c).
Their molecular structures are shown in Fig. 1. Drug compounds
were dissolved in dimethyl sulfoxide (DMSO) and stored at 4 C.
Immediately before use, drugs were pre-diluted in RPMI media to
the desired concentration. The final DMSO concentration did not
exceed 1% (v/v) and had no effect by itself on the proliferation of the
parasites.
2.3. In vitro compound activity against trypanosomes
Epimastigotes of T. copemani G1 and G2, and T. cruzi 10R26
strains in the log phase of growth were diluted in RPMI media to
1  106 parasites/ml. 100 ml of parasite suspension (1  105 para-
sites/well) was seeded into 96-well flat-bottom plates (Corning,
Corning, N.Y.), and then incubated at 28 C in a seven-fold dilution
series covering a range from 1 mM to 0.004 mM for melarsoprol, and
10 mMe0.013 mM for the remainder of the drugs. All concentration
rangeswere selected based on initial screenings at 10 and 1 mM that
showed percentages of inhibition greater than 50% at 10 or 1 mM.
Each drug concentration was evaluated in triplicate. Control wells
with only compounds and with only parasites (without com-
pounds) were included. After 48 h of compound exposure, 15 ml of
AlamarBlue® (Resazurin-AbD Serotec) was added to each plate
allowing for a colour change through metabolic oxidation-
reduction by viable trypanosomes. Plates were incubated for an
additional 24 h. After this time, absorbance was quantified using a
Dynexmicroplate reader at an excitationwavelength of 570 nm and
emission wavelength of 590 nm. The percentage of inhibition was
Fig. 1. Molecular structure of lead compounds.
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average of triplicate data points. The concentration (mM) of the drug
necessary to inhibit 50% of cell proliferation of that observed in
control cultures (parasites grown in the absence of test compound)
was calculated (IC50). Graphs were created and analysed using the
statistical software program Prism (GraphPad Software Inc., San
Diego, Cali). The statistical significance of results was estimated by
2way ANOVA. Each experiment was performed on three indepen-
dent occasions.2.4. In vitro compound toxicity in L6 cells
An evaluation of mammalian cell cytotoxicity was carried out in
parallel. 100 mL of RPMI 1640 medium supplemented with 10%
foetal bovine serum and containing 5  103 L6 cells were seeded
into 96-well plates. Plateswere incubated overnight at 37 C and 5%
CO2 and then drugged with seven 3-fold dilutions covering a range
from 10 mM to 0.013 mM for melarsoprol and miltefosine, and
100 mMe0.13 mM for the remainder of the drugs. Control wells with
only compounds and with only cells were included. After 72 h of
incubationwith the drugs, plates were inspected under an inverted
microscope to assure growth of cells in the control wells (not
drugged) and sterile conditions. 15 mL of AlamarBlue® was then
added towells and the plates incubated for another 2 h at 37 C and
5% CO2. Absorbance was quantified using a Dynex microplate
reader at an excitation wavelength of 570 nm and emission wave-
length of 590 nm. Podophyllotoxinwas used as a reference drug fortoxicity. The therapeutic index (TI) of all drugs was calculated as
TD50/ED50, where TD50 is the dose of drug that causes a toxic
response in 50% of the L6 cells (IC50 value for cytotoxicity) and
ED50 is the dose of drug that is active in 50% of trypanosomes (IC50
value for anti-trypanosomal activity). When IC50 values for toxicity
were higher than 100 mM, this concentration value was used to
calculate the therapeutic index (TI). The statistical significance of
results was estimated by 2way ANOVA. Each experiment was per-
formed on three independent occasions.3. Results
3.1. In vitro compound efficacy of reference drugs
The reduction of resazurin, converted from blue to a bright-red
colour by metabolically active trypanosomes/cells, was used as an
indicator of viability of trypanosomes and L6 cells and therefore as a
measure of drug activity and toxicity respectively. All reference
drugs exhibited potent in vitro activity against all trypanosomes.
However, both strains of T. copemani were more susceptible to all
drugs than T. cruzi. Benznidazole was approximately eight times
more active against T. copemani G1 (IC50 1.053 mM) and G2 (IC50
0.713 mM) than against T. cruzi (IC50 8.537 mM) (Fig. 2).
Posaconazole exhibited similar activity against T. cruzi and
T. copemani G2, both with an IC50 of 5.429 mM and 6.147 mM
respectively. This drug was more active against T. copemani G1,
which exhibited an IC50 of 1.254 mM. Melarsoprol and miltefosine
Fig. 2. Sigmoidal dose-response curves of T. copemani G2 and T. cruzi drugged with benznidazole. X-axis: percentage of inhibition. Y-axis: drug concentration.
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melarsoprol was muchmore activewith IC50s in the sub-mM range.
Significant differences in drug susceptibility between T. copemani
G1 and G2 (p < 0.0001) were found. T. copemani G2 was more
susceptible to benznidazole and melarsoprol. In contrast,
T. copemani G1 was more susceptible to melarsoprol and miltefo-
sine (Table 1, Fig. 3).Fig. 3. Drug susceptibility of T. copemani G1 and G2, and T. cruzi against reference
drugs. X-axis: IC50. Y-axis: drugs. Bars: standard deviation.3.2. In vitro compound efficacy of fenarimol and pyridine
derivatives
All lead compounds exhibited potent in vitro activity against all
trypanosomes in the low and sub-mM range. However, they were
more active against both strains of T. copemani, with the exception
of PDB1 which was less active against T. copemani G2 than T. cruzi
(Table 2). All four compounds exhibited similar activity against
T. cruzi, with IC50 values ranging from 4.5 mM to 6.1 mMFN2was the
compound that presented the highest activity against both
T. copemani G1 and G2, with IC50 of 1.122 mM for G1 and 0.969 mM
for G2. There was a significant difference in susceptibility between
the two T. copemani strains to all compounds (p < 0.0001), with
T. copemaniG2more susceptible to FN1 and FN2 and T. copemaniG1
more susceptible to FN2 and PDB2 (Table 2, Fig. 4).Table 1
Inhibitory concentration 50 (IC50) of all reference drugs against T. copemani G1 and G2,





















() Therapeutic indices are given in parenthesis.
a Reference drug for toxicity.3.3. In vitro drug toxicity in L6 cells
The therapeutic index (TI) of all compounds was calculated for
each parasite (Tables 1 and 2). The highest cytotoxicity for L6 cells
was exerted by melarsoprol (IC50, 0.062 mM) and miltefosine
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(6.2)
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Inhibitory concentration 50 (IC50) of lead compounds against T. copemani G1 and G2, and T. cruzi, and toxicity against L6 cells. Values are in mM. SD: standard deviation.
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Fig. 4. Drug susceptibility of T. copemani G1, G2, and T. cruzi against lead compounds.
X-axis: IC50. Y-axis: drugs. Bars: standard deviation.
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both drugs was in general significantly low (Melarsoprol TI < 12.1
and Miltefosine TI < 2.4) suggesting the effect of the drugs was in
part due to cytotoxicity instead of only to anti-trypanosomal ac-
tivity (Table 1). FN2 and PDB2 compounds exhibited IC50s of
59.52 mM and 50.06 mM respectively in L6 cells, followed by
benznidazole, posaconazole, FN1 and PDB1, which exhibited IC50s
higher than 100 mM. However, benznidazole and FN1 presented a
better TI against both T. copemani strains, and PDB1 exhibited a
better TI against T. cruzi than benznidazole and posaconazole
(Tables 1 and 2).4. Discussion
The effect of different drugs and new compounds on the growth
of two strains of T. copemani and one strain of T. cruzi was inves-
tigated and compared using the AlamarBlue® assay. The Ala-
marBlue® assay is a sensitive and reproducible method to measure
the viability of different cell lines (Ansar Ahmed et al., 1994). It has
been extensively used to determine the in vitro activity/toxicity of
different drugs against different trypanosomatids such as T. cruzi, T.
brucei and Leishmania spp. (Rolon et al., 2006; Sykes and Avery,
2009; Morais-Teixeira et al., 2011; Bowling et al., 2012; Sales Ju-
nior et al., 2014; Engel et al., 2015). A previous study found Ala-
marBlue® was a good method to quantify the activity of different
compounds against T. brucei gambiense and T. b. rhodesiense in vitro
and demonstrated that results were comparable to those obtained
with other fluorochrome dyes (R€az et al., 1997). Furthermore, Ala-
marBlue® has been shown to be slightly superior in sensitivity to
the MTT cell proliferation assay (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), which has been extensively usedin high throughput screenings (Hamid et al., 2004; Ho et al., 2012).
The results of the present study showed IC50 values for benzni-
dazole and miltefosine similar to IC50 values reported in previous
studies for T. cruzi, confirming the reliability and reproducibility of
this assay (Santa-Rita et al., 2000; Lira et al., 2001; Saraiva et al.,
2002; Luna et al., 2009; Moraes et al., 2014).
The present study is the first to be carried out looking at the
in vitro susceptibility of Australian trypanosomes to different drugs
and new compounds developed against different trypanosomatids.
All reference drugs, benznidazole, posaconazole, melarsoprol and
miltefosine, displayed promising trypanocidal activity against the
epimastigotes of both strains of T. copemani isolated from the
critically endangered woylie and against T. cruzi, showing a broad
anti-trypanosomal spectrum. Previous studies have also demon-
strated that some of these reference drugs present a broad-
spectrum of activity. Miltefosine for example, originally devel-
oped as an anticancer agent and now used for treatment of both
visceral and cutaneous leishmaniasis, has also been shown to be
active in vitro against T. cruzi, with an IC50 ranging from 1 mM to
3.5 mM (Santa-Rita et al., 2000; Lira et al., 2001; Saraiva et al., 2002).
Melarsoprol, mainly used against late-stage sleeping sickness
(Schweingruber, 2004), has also been shown to be active in vitro
and in vivo against T. lewisi (Howie et al., 2006; Verma et al., 2011;
Dethoua et al., 2013).
Miltefosine was active against T. cruzi and T. copemani G1 and
G2, with IC50s of 0.095 mM, 0.745 mM and 2.1 mM respectively.
However, it has been shown to present significantly lower activity
in vitro and in vivo against T. brucei subspecies with 18-fold and 43-
fold greater IC50 values of 35.5 mM for T. brucei and 47.0 mM for
T. brucei rhodesiense in in vitro experiments (Croft et al., 1996), and
76 mM for T. brucei gambiense and 88 mM for T. brucei rhodesiense in
experimentally infected mice (Konstantinov et al., 1997). The sig-
nificant differences in miltefosine activity between species is not
surprising if we take into account the fact that antiparasitic drugs
are usually developed to target and/or inhibit intracellular signaling
pathways that are crucial in cell replication and survival, and those
pathways may differ between species. Hence, the significant simi-
larities in the activity of miltefosine against both T. cruzi and
T. copemani may be due to intrinsic similarities between them in
the target site of the drug. However, the mechanism of action of
miltefosine is not known.
Benznidazole and posaconazole demonstrated lower activity
against T. cruzi than the drugs miltefosine and melarsoprol. Similar
studies evaluating the susceptibility of different strains of T. cruzi to
miltefosine found this drug had a greater activity against each
strain than the reference drug benznidazole with IC50s ranging
between 0.9 mM and 3.0 mM for miltefosine and 9.0 mMe27 mM for
benznidazole (Saraiva et al., 2002; Luna et al., 2009). However, it
cannot be ignored that miltefosine and melarsoprol exhibited the
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therapeutic indices. This suggests that the greater activity of both
drugs against T. cruzi and T. copemani may not be entirely due to
their trypanocidal activity. This is not the first study showing
toxicity of melarsoprol and miltefosine in mammalian cell lines.
Melarsoprol has been shown to induce programmed cell death or
apoptosis in leukemic and plasma cell lines in vitro (K€onig et al.,
1997; Rousselot et al., 1999) as well as miltefosine in numerous
tumour cell lines (Engelmann et al., 1995; Henke et al., 1998;
Rybczynska et al., 2001).
All fenarimol and piridyne derivatives exhibited potent activity
against T. cruzi and T. copemani epimastigotes. Moreover, these four
compounds showed better activity against T. cruzi than the T. cruzi
reference drug, benznidazole. These results are consistent with
those obtained by Keenan (Keenan et al., 2013c), who showed that
both FN1 and FN2 exhibited curative activity in mice infected with
the Tulahuen strain of T. cruzi and significant activity in vitro against
T. cruzi amastigotes, as well as low toxicity in L6 cells. However, the
T. cruzi IC50s of both fenarimol compounds obtained in the present
study are generally higher than those previously reported (Keenan
et al., 2013c). Moreover, Moraes (Moraes et al., 2014) found that
amastigotes of the T. cruzi strains Y, CL, and Tulahuen, and the
clones Dm28c, ARMA13 cl1, 92-80 cl2, and ERA cl2, exhibited better
IC50s for posaconazole, PDB1 and PDB2 compared with our
findings.
These discrepancies may be due to the use of different T. cruzi
strains but most probably because different trypanosome life cycle
stages were used in both studies. Several studies have revealed that
some drugs or compounds, including benznidazole, are more active
against T. cruzi intracellular amastigotes compared to epimastigotes
and trypomastigotes (Freire-de-Lima et al., 2008; Luna et al., 2009;
Sales Junior et al., 2014). This has also been shown with different
species of Leishmania, where intracellular amastigotes showed
greater susceptibility to miltefosine, than promastigotes (Obonaga
et al., 2014). This diverse degree of activity that some drugs pre-
sent in different life-stages of the parasite, has been shown to be
related to the capacity of the drug to exert anti-trypanososmatid
action independently of cell-mediated parasiticidal mechanisms
(Vermeersch et al., 2009). For example, a greater susceptibility of
Leishmania amastigotes than promastigotes to miltefosine was
suggested to be the result of increased cytotoxicity within the
macrophage, conferred by alkyl-lysophospholipids promoting the
death of intracellular parasites as a secondary effect on host cells by
oxidative burst or production of reactive-oxygen metabolites
(Azzouz et al., 2005). Although, we previously demonstrated that
T. copemani G2 is able to invade L6 and VERO cells in vitro, the
parasite was not able to replicate inside cells (Botero et al., 2016).
Therefore, testing the drugs on intracellular amastigotes could not
be achieved. The use of a better in vitromodel, possibly a marsupial
derived cell line, that could support the intracellular growth of
T. copemani will be necessary to test all drugs on amastigotes.
Moreover, complementary in vivo studies using a murine or any
other in vivomodel are required as a next step to better understand
T. copemani drug susceptibility on natural hosts.
T. copemani G1 and G2, although grouped within the same clade
in a phylogeny, exhibited genetic differences in both the 18SrDNA
and gGAPDH genes (Botero et al., 2013). Furthermore, T. copemani
G1 has always been found in blood of marsupials while T. copemani
G2 has also been found in tissues (Botero et al., 2013). Interestingly,
we found that both strains of T. copemani exhibited significant
differences in susceptibility to the different drugs used, supporting
previous findings that genetic variation/gene varinats within spe-
cies determines the degree of susceptibility to drugs (Campos et al.,
2011; Plourde et al., 2012; Graf et al., 2013, 2016; Laffitte et al.,
2016). Previous studies have shown an association betweenT. cruzi genetic diversity and their susceptibility to different drugs.
Moraes (Moraes et al., 2014) reported a different response to the
drugs benznidazole, posaconazole, EPL-BS967 (PDB1), and EPL-
BS1246 (PDB2) among genetically different T. cruzi strains from
all different DTUs (discrete typing units). Moreover, the observation
of differences in susceptibility to benznidazole among several
T. cruzi strains isolated from humans, vectors and marsupials has
also been reported (Toledo et al., 1997). Phylogenetic studies have
shown considerable intra-specific genetic variability within
T. copemani isolates and the presence of co-infections with different
T. copemani genotypes/strains in naturally infected animals (Botero
et al., 2013). This variability and its possible association with the
different phenotypic responses to drugs may complicate the sce-
nario and may have important consequences on future attempts to
combat T. copemani infections.
Finally, the fact that benznidazole and FN2 had better thera-
peutic indices against T. copemani G1 and G2 compared with the
other drugs (Benznidazole TI > 94.9 and TI > 140.2; FN2 TI > 53.1
and TI > 61.4) suggests these drugs could be potentially used as
possible therapeutics for ameliorating the clinical effects of in-
fections with this parasite in wildlife. However, in vivo trials are
needed before they can be used in wildlife.
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